Identification of N-ethyl-α-ethylphenethylamine in crystalline powder seized for suspected drug trafficking: A research chemical or a new designer drug?

Forensic Toxicology

Volumn 31, Issue 1, 2013, Pages 54-58

  Lee, Jaesin ^a   Choe, Sanggil ^a   Choi, Hyeyoung ^a   Heo, Sewoong ^a   Kim, Eunmi ^a   Kim, Hyunju ^b   Bang, Eunjung ^b   Chung, Heesun ^a  

^a National Forensic Service   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Drug trafficking; GC EI MS; LC TOF MS; N Ethyl ethylphenethylamine; NMR; Structural elucidation

Indexed keywords

DESIGNER DRUG; N ETHYL ALPHA ETHYLPHENETHYLAMINE; NARCOTIC AGENT; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; CRYSTALLINE POWDER; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG TRAFFIC; FORENSIC IDENTIFICATION; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POWDER; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84872683572     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-012-0158-1     Document Type: Conference Paper

References (18)

1. Namera A, Nakamoto A, Saito T, Nagao M (2011) Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review. Forensic Toxicol 29:1-24
2. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Fereirós N (2009) 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832-837
3. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2011) Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylidoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol 29:25-37
4. - 2011 Annual report of the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, November 2011
5. World Drug Report (2011) United Nations Office of Drugs and Crime (UNODC). June, Vienna 2011
6. Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45:330-340
7. Zaitsu K, Katagi M, Tatsuno M, Sato T, Tsuchihasi H, Suzuki K (2011) Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol 29:73-84
8. Zuba D (2012) Identification of cathinones and other active components of 'legal highs' by mass spectrometric methods. Trends Anal Chem 32:15-30
9. Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12-15
10. Gibbons S, Zloh M (2010) An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 20:4135-4139
11. Maheux CR, Copeland CR, Pollard MM (2010) Characterization of three methcathinone analogs: 4-methylmethcathinone, methylone, and bk-MBDB. Microgram J 7:42-49
12. Theobald DS, Maurer HH (2007) Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem Pharmacol 73:287-297 (Pubitemid 44855724)
13. Rösner P, Quednow B, Girreser U, Junge T (2005) Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). Forensic Sci Int 148:143-156 (Pubitemid 40082404)
14. Gosav S, Dinica R, Praisler M (2008) Choosing between GC-FTIR and GC-MS spectra for an efficient intelligent identification of illicit amphetamines. J Mol Struct 887:269-278
15. Junet R (1956) Ethylamphetamine in the treatment of obesity. Praxis 45:986-988 (article in French)
16. Oberlender R, Nicholas DE (1991) Structural variation and (+)-amphetamine like discriminative stimulus properties. Pharmacol Biochem Behav 38:581-586
17. Nicholas DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313
18. Misuse of Drugs Act 1971. Parliament of the United Kingdom, May 1971